ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RAPP
SNDX (17) VSTM (36) AMPH (72) SLN (44) ⌘ Pro Terminal →

Rapport Therapeutics Inc. (RAPP) — RQD Stock Rating Cockpit

$25.13 +0.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.10

Rapport Therapeutics Inc. (RAPP) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.20B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RAPP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $25.13 (+0.32% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RAPP ranks #787 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RAPP compare to SNDX and VSTM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and VSTM (Verastem Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RAPP?
▼

Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $350.3M in revenue (+50.6% YoY), -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $25.10 (-0.13%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (7)Whales (4)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$56 Bull$22 Base$17 Bear
📬 FREE RAPP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RAPP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY RAPP SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$28.99+1.3% Next Q
Q2 (-2Q)
35
Grade E$29.37-6.2% Next Q
Q3 (-1Q)
33
Grade E$27.54-8.8% Next Q
Current
30
Grade E$25.13-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RAPP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RAPP currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($35.74) and Max Pain ($26.39) forces dealer call-delta covering toward $55.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RAPP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RAPP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
38.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE10% OF RANGE
L: $22$25.13H: $53
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on RAPP

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-22.9% ROIC with 42.0% gross margin and -7.58% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

7/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like RAPP
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RAPP)

  • ✓Walkthrough of RAPP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RAPP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.27%📐 HORIZONTAL RANGE
2026-11-03O $24.21H $25.13L $24.21C $25.13VOL 926.6K
RES: $60.43SUP: $21.64SMA50: $35.74SMA200: $35.63
$55.09$46.14$37.19$28.23$19.28RES $60.43SUP $21.64$25.132026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RAPP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RAPP Butterfly Map → + Track RAPP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +50.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RAPP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RAPP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RAPP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RAPP)

Health Care Rank #787 of 1015 ⚔️ SNDX vs RAPP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RAPP vs. SNDX, VSTM, AMPH, SLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Rapport Therapeutics Inc. (RAPP) ranks #787 by composite RQD confidence (30/100, grade E) and #333 by equity capitalization ($1.20B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with RAPP at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RAPP ACTIVE
Rapport Therapeutics Inc.
E 30/100 — — -22.9% +0.32% $1.20B Benchmark Subject
SNDX
Syndax Pharmaceuticals Inc.
E 17/100 — — -35.0% -4.03% $1.22B /sndx-vs-rapp →
VSTM
Verastem Inc.
D- 36/100 — — -35.0% -1.64% $1.18B /vstm-vs-rapp →
AMPH
Amphastar Pharmaceuticals Inc.
B 72/100 11.7x 49.5% 9.0% -2.49% $1.18B /amph-vs-rapp →
SLN
Silence Therapeutics Plc American Depository Share
D 44/100 — 61.5% -35.0% +0.05% $1.23B /sln-vs-rapp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002012593 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapport Therapeutics Inc. (RAPP) reported GAAP revenue of $350.3M (+50.6% vs. FY2024 revenue of $232.6M , and +245.8% cumulative change since FY2023) , GAAP net income of -$111.5M, operating cash flow of -$87.5M, and free cash flow of -$88.1M (-31.0% YoY). On the balance sheet, RAPP closed FY2025 with $512.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $350.3M -$111.5M -$87.5M -$88.1M $512.4M —
FY2024 (FY) 2024-12-31 $232.6M -$78.3M -$64.8M -$67.2M $314.9M —
FY2023 (FY) 2023-12-31 $101.3M -$34.8M -$27.2M -$27.2M — —

3. RAPP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $25.13 (+0.32% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RAPP ranks #787 in composite RQD confidence.

How does RAPP compare to SNDX and VSTM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and VSTM (Verastem Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RAPP?

Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $350.3M in revenue (+50.6% YoY), -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RAPP trading relative to its 50-day, 200-day, and 52-week technical levels?

RAPP last traded at $25.13 (+0.32% on volume of 1,327,819 shares), positioning the stock -29.69% below its 50-day simple moving average ($35.74) and -29.47% below its 200-day simple moving average ($35.63). Across its 52-week range of $22.06 to $52.93, RAPP sits at the 9.9% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($21.99 to $28.27).

Direct Sub-Reports: RAPP RQD Cockpit RAPP 12M Forecast RAPP Earnings & Move RAPP Dividends & DRIP RAPP Insiders & 13F RAPP Whale Options RAPP Profit Sankey RAPP News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

RAPP — Rapport Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Rapport Therapeutics Inc. (RAPP) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $25.13 (+0.32% 1D, market capitalization $1.20B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -22.9%, gross margin of —, operating margin of —, and free cash flow yield of -7.58%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rapport Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile states a market capitalization of $1.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Rapport Therapeutics Inc. (RAPP) reported $350.3M in annual revenue (up from $232.6M in FY2024, +50.6% YoY) and -$111.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($101.3M revenue, -$34.8M net income) through FY2025, RAPP scaled operating cash flow to -$87.5M and free cash flow to -$88.1M, backed by $512.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.58% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $22.06 – $52.93 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only cross-company reference in the news wire is the AbbVie market mention, which is a headline reference and does not establish a supply-chain link in the source data.

  • Key Question #1: Can RAPP sustain or expand its — operating margin and -22.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $350.3M and free cash flow of -$88.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RAPP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RAPP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rapport Therapeutics Inc. (RAPP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RAPP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RAPP Bull vs. Bear Conversation Board — What's Your Call at $25.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RAPP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RAPP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $32.56 (+30.0%)
📌 Pinned Debate

The stock trades at $24.21 after a 7.6% gain, roughly 54% above its $22.06 52-week low, with a $1.16B market cap relative to a $52.6M c

Here is why I am bullish on RAPP here at $25.05: The stock trades at $24.21 after a 7.6% gain, roughly 54% above its $22.06 52-week low, with a $1.16B market cap relative to a $52.6M cash balance.. Compare RAPP's 0.0% operating margin and -22.9% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $23.80 are getting bought.

SectorRotator 🐂 BULL

@BreakoutHunter Agree on the RQD 30/100 quality, though with 1.0 beta I'm scaling in with half-size at $25.05 and keeping dry powder in case we test $23.30.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $19.79 (-21.0%)
Spot @ $25.05

Operating losses widened from -$36.2M in FY 2023 to -$125.1M in FY 2025 while the Roarable RQD rating scores the company 31 with a Piot

Operating losses widened from -$36.2M in FY 2023 to -$125.1M in FY 2025 while the Roarable RQD rating scores the company 31 with a Piotroski F-Score of 2/9.. Look at the math on RAPP: paying current EV/EBITDA multiples for -22.9% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $22.04 before getting long.

LIVE TAPE